Stay updated with breaking news from Evaluate Early. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data from the SPHERE registry revealed racial and ethnic discrepancies in disease severity, comorbidities, and outcomes experienced by patients with pulmonary arterial hypertension (PAH) receiving selexipag.
Researchers used real-world data to further validate the use of selexipag in the management of pulmonary arterial hypertension (PAH).
Plasma cell-free DNA, a marker of cellular injury, is elevated in patients with pulmonary arterial hypertension, correlates with disease severity, and predicts worse survival, new research shows.
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today 11* abstracts highlighting data from its pulmonary hypertension (PH)...